Safety and pharmacokinetics of alfuzosin 10 mg once daily formulation comparatively to standard formulation (2.5 mg tid) in elderly subjects

Pinquier, Jean‐Louis; Fuder, H.; Amersdorffer, Jutta; Lilienthal, N.; Rauch‐Dessanti, C.; Delfolie, A.; Rosenzweig, P.

doi:10.1016/s0009-9236(99)80337-3

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The properties of once-daily formulation of alfuzosin were studied in an elderly population without finding any pharmacokinetic difference in 16 healthy volunteers between 66 and 78 years. 24 Despite 35% greater concentration of alfuzosin in patients aged ⩾75 years, 22 clinical trials showed no overall differences in safety or effectiveness between subjects ⩾65 years, ⩾75 years and younger men. 22…”

Section: Alfuzosin: Pharmacology and Pharmacodynamicsmentioning

confidence: 98%

“…23 The properties of once-daily formulation of alfuzosin were studied in an elderly population without finding any pharmacokinetic difference in 16 healthy volunteers between 66 and 78 years. 24 Despite 35% greater concentration of alfuzosin in patients aged ⩾75 years, 22 clinical trials showed no overall differences in safety or effectiveness between subjects ⩾65 years, ⩾75 years and younger men. 22 As regards the pharmacodynamic profile of alfuzosin in special populations, the presence of chronic heart failure has not been found to significantly affect the pharmacokinetics of 10 mg daily alfuzosin.…”

Section: Alfuzosin: Pharmacology and Pharmacodynamicsmentioning

confidence: 98%

See 1 more Smart Citation

Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis

Mari

Antonelli

Cindolo

et al. 2021

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Background: Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are a bothersome frequent symptom in adult males. This systematic review analyzed the available evidence on the pharmacokinetic and pharmacodynamic features of alfuzosin, and its clinical efficacy both as monotherapy and in combination with other drugs for the treatment of male LUTS/BPH. Methods: A systematic review of the last 10 years was performed using the MEDLINE, EMBASE and Cochrane libraries in March 2020. The protocol for this systematic review was registered on PROSPERO (Central Registration Depository: CRD42020136120) and is available in full on the University of York website. Results: Alfuzosin is a quinazoline derivative and, although a nonspecific α1-blocker, exhibits a selective concentration in the prostate compared with plasma in patients with BPH. Three registration trials assessed the safety and efficacy of alfuzosin. The 10 mg daily formulation has a three-layered matrix containing the active substance between two inactive coats allowing a drug release over 20 h. Alfuzosin showed high tolerability, few vasodilatory effects and a low rate of ejaculation disorders over older alpha-blocking compounds thanks to the high uroselectivity of alfuzosin and its preferential concentration at urinary level. Six randomized clinical trials (RCTs) assessed efficacy and safety of alfuzosin versus other alpha-blockers ± placebo: three studies comparing with tamsulosin, one with doxazosin, and two with silodosin or tamsulosin. One RCT investigated the clinical outcomes of alfuzosin with finasteride, two with propiverine and two with phosphodiesterase-5 inhibitors. Conclusions: Alfuzosin is an effective drug for the treatment of LUTS/BPH, with a lower rate of sexual disorders compared with other alpha-blockers. Alfuzosin is also safe with low adverse events in case of concomitant antihypertensive therapy and in patients with cardiovascular morbidity. Safety and efficacy of alfuzosin has been reported also in case of combination therapy with antimuscarinic agents and PDE5i.

show abstract

Section: Alfuzosin: Pharmacology and Pharmacodynamicsmentioning

confidence: 98%

Section: Alfuzosin: Pharmacology and Pharmacodynamicsmentioning

confidence: 98%

Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis

Mari

Antonelli

Cindolo

et al. 2021

Therapeutic Advances in Urology

View full text Add to dashboard Cite

show abstract

Extended-release alfuzosin hydrochloride: A new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia

Guay

2004

The American Journal of Geriatric Pharmacotherapy

View full text Add to dashboard Cite

Alfuzosin

McKeage¹,

Plosker²

2002

Drugs

View full text Add to dashboard Cite

Prolonged-release alfuzosin 10mg once daily controls symptoms associated with BPH throughout a 24-hour dosage interval as effectively as immediate-release alfuzosin 2.5mg three times daily but with fewer vasodilatory adverse events. A nonblind extension study showed that clinical benefits were maintained for up to 1 year and the once-daily 10mg formulation continued to be well tolerated, particularly in terms of cardiovascular effects and sexual function. Thus, for the medical management of men with BPH, prolonged-release alfuzosin 10mg is an effective, well tolerated and convenient treatment option.

show abstract

Safety and pharmacokinetics of alfuzosin 10 mg once daily formulation comparatively to standard formulation (2.5 mg tid) in elderly subjects

Abstract: Clinical Pharmacology & Therapeutics (1999) 65, 202–202; doi:

Cited by 3 publications

References 0 publications

Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis

Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis

Extended-release alfuzosin hydrochloride: A new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia

Alfuzosin

Contact Info

Product

Resources

About